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INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma (NHL), accounting for roughly 30% of newly diagnosed cases in the United States. DLBCL is a heterogeneous lymphoma consisting of activated B cell (ABC) and germinal center B cell-like (GCB) subtypes that have different gene expression profiles, oncogenic aberrations, and clinical outcomes (1, 2) . Compared with the GCB subtype, ABC-DLBCL has a significantly lower survival rate after multiagent chemotherapy (3) and is characterized by chronically active B-cell receptor (BCR) signaling (4) , which is required for cell survival. Therefore, components of the BCR signaling pathway are emerging as attractive therapeutic targets in the ABC subtype of DLBCL.
Bruton's tyrosine kinase (BTK), pivotal to BCR signaling, is covalently bound by ibrutinib with high affinity. Ibrutinib is a first-in-class, once-daily, oral inhibitor of BTK that is approved by the US FDA for the treatment of patients with chronic lymphocytic leukemia (CLL), including those with deletion 17p, patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, and those with Waldenström's macroglobulinemia. With respect to DLBCL, a phase I/II clinical trial showed an overall response rate of 37% in the ABC subtype (5) with single-agent ibrutinib therapy.
Tumor responses to single-agent kinase inhibitor therapies are often limited by the cell's ability to bypass the target via alternative pathways or acquired mutations in the target or its pathway (6, 7) . It has been shown that a small number of CLL patients acquire resistance to ibrutinib through mutations in BTK and its substrate phospholipase C gamma 2 (PLCG2) following prolonged treatment (8, 9) . In addition to acquisition of these mutations, other mechanisms of resistance, such as upregulation of potentially on October 28, 2017. © 2017 American Association for Cancer Research. mct.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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Through screening of parental and acquired ibrutinib-resistant cell lines, we have identified and report here that a B-cell lymphoma 2 (BCL-2) inhibitor,  synergizes with ibrutinib in vitro and in vivo and is able to overcome the ibrutinibresistant phenotype in tumor cells overexpressing BCL-2. cells were generated by in vitro culture of the parental cell lines for prolonged periods of time with progressively increasing concentrations of ibrutinib.
Generation of BTK-WT and BTK-C481S cell lines
Custom BTK-plasmid constructs expressing either the wild-type BTK (BTK-WT) or BTK genes containing a single mutation C481S (BTK-C481S) were obtained from GeneCopoeia with the Lv201 lentiviral backbone. Plasmids were amplified, purified, and sequenced by System Biosciences. Plasmids (5.0 µg) were then used to transfect 293T cells in a 10-cm dish using a lentiviral packaging kit (GeneCopoeia) following the manufacturer's instructions. Media were removed 16 hours after transfection, and fresh media were added to the dish and incubated for 24 hours. Virus-containing supernatants were harvested and filtered (0.2-µm filter) and used for TMD8 transduction.
TMD8 cells were plated in 6-well plates in 2-mL medium at the concentrations of 1 × 10 6 cells/mL. Virus supernatants (500 µL) were added to wells followed by DOTAP Liposomal Transfection Reagent (final concentration 10 µg/mL; Sigma). Plates were centrifuged for 1 hour at 2,000 rpm and kept in culture at 37°C overnight. Supernatants were removed and cells were resuspended in fresh medium and incubated for 2 days.
Cells were selected using 0.2 µg/mL puromycin to generate stable cell lines.
OCI-LY10 (BTK-C481S) was generated by introducing mutant HIS 6 /Strep-tagged BTK (C481S) under control of the EF1α promotor into the OCI-LY10 cell line using lentiviral transduction. Transduced cells were selected using blasticidin as an antibiotic resistance marker.
Cell viability assays
CellTiter-Glo® (Promega) luminescent cell viability assay was performed according to the manufacturer's instructions. Briefly, cells were seeded at 8,000 to 25,000 cells/well in a 96-well plate in the presence of single drugs or drug combinations for 3 or 5 days.
The number of viable cells in culture was determined by quantification of ATP present, which was proportional to luminescent signal detected. Combination index (CI), a drug (12) .
qRT-PCR assays
The TaqMan® Fast Cells-to-C T ™ Kit (Life Technologies) was used to extract total RNA and reverse transcribe RNA to cDNA according to the manufacturer's specifications. 
Western blot
Cells were washed twice with ice-cold phosphate-buffered saline and lysed with RIPA buffer (R0278, Sigma-Aldrich) supplemented with 1× protease/phosphatase inhibitor.
Cell lysates were subjected to SDS-PAGE separation and subsequently transferred on October 28, 2017. © 2017 American Association for Cancer Research. mct.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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siRNA transfection
Accell human SMARTpool siRNAs targeting MAP3K7 (E-003790-00-0005) or IRAK4 (E-003302-00-0005) were purchased from Dharmacon. TMD8 cells (1 × 10 6 /mL) were incubated with the Accell delivery medium (1% FBS) containing 1 µM of siRNAs at 37°C according to the manufacturer's instructions. After overnight incubation, fresh delivery medium (1% FBS) was added to each well. Cells were harvested 3 days after transfection and used for qRT-PCR.
Xenograft study
All animal studies were completed under the Institutional Animal Care and Use Committee (IACUC)-approved protocols for animal welfare. CB17 SCID mice (Charles daily with ibrutinib (12 mg/kg), ABT-199 (40 mg/kg), or the combination of both by oral gavage, with 10 mice per group. Tumor volume was measured twice a week and calculated as tumor volume = (length × width 2 ) × 0.5.
Apoptosis assays
The ApoDETECT™ Annexin V-FITC Kit (Life Technologies) was used to quantify the apoptotic cell population according to the manufacturer's specifications. Briefly, cells were washed with ice-cold phosphate-buffered saline and resuspended in 1× binding buffer at a concentration of 5 × 10 5 cells/mL. Annexin V-FITC (10 µL) was added to 190 µL of cell suspension and incubated at room temperature for 10 minutes. After being washed with 1× binding buffer, cells were resuspended in 190 µL of binding buffer with 10 µL of 20 µg/mL propidium iodide (PI) and analyzed by flow cytometry. Figure 1A ). In addition, BCL2
Colony formation assays
is the only gene in the BCL-2 family with an anti-apoptotic function that was significantly increased (P < 0.05, Supplemental Table 1 ). The upregulation of BCL2 gene expression was confirmed by qRT-PCR ( Figure 1B ). An increase in BCL2 gene expression was also observed in ibrutinib-resistant DoHH2 cells ( Figure 1C ). Consistent with its increased gene expression, a higher level of BCL-2 protein was detected in ibrutinibresistant cells ( Figure 1D ). In addition to increased BCL2 expression, our microarray analyses showed reduced levels of MCL1 and BCL2A1 in ibrutinib-resistant cells.
Reduction of both MCL1 and BCL2A1 may contribute to higher ABT-199 sensitivity in the ibrutinib-resistant cells (13) (14) (15) . Indeed, ibrutinib-resistant TMD8 cells were much more sensitive to ABT-199 than TMD8 parental cells ( Figure 1E ).
The identification of MYD88 L265P mutations in ABC-DLBCL suggests the importance of Toll-like receptor (TLR) signaling in this malignancy (16 chronically active BCR signaling in addition to TLR pathways (5) . Similar to chronically active BCR signaling, TLR signaling also contributes to the activation of the NF-κB pathway (17) , which is involved in the transcriptional regulation of BCL2 (18) .
Stimulation with a TLR9 agonist (ODN 2216) resulted in a 20-fold increase in the EC 50 of ibrutinib in TMD8 cells. Intriguingly, we observed a 1.42-fold increase in MAP3K7 (P = 0.028) and a 1.83-fold increase in IRAK4 (P = 0.004) in ibrutinib-resistant TMD8 cells.
We additionally observed a 6.69-fold reduction in the negative regulator of TLR signaling, IRAK3 (P = 0.052), in ibrutinib-resistant TMD8 cells. To investigate the role of TLR signaling in regulating BCL2 gene expression, we stimulated TMD8 cells with a TLR9 agonist, CpG ODN 2216, and detected an increased BCL2 level compared with the control ODN treated cells ( Figure 1F ). Consistently, knockdown of MAP3K7 or IRAK4 using siRNA reduced BCL2 gene expression ( Figures 1G and 1H) . Therefore, we postulate that resistant cells have upregulated TLR pathways, which lead to an increase in BCL2 gene expression. However, we believe that further mechanistic characterization of this interesting question is beyond the scope of this manuscript.
In addition to BCL2, we identified several genes with 3-10-fold increases in expression in the ibrutinib-resistant TMD8 cells (P < 0.05, Supplemental Table 2 ) and another subset of genes with 3-10-fold reductions in expression (P < 0.05, Supplemental Table   3 ). Gene expression was analyzed in clinical pretreatment FFPE specimens from the PCYC-1106 study, a phase II trial testing single-agent ibrutinib in patients with DLBCL.
BCL2 was found to be differentially expressed in ABC-DLBCL and GCB-DLBCL patient samples, with ABC-DLBCL samples having higher BCL2 gene expression than those from patients with GCB-DLBCL (Figure 2A ). Three of 18 (17%) GCB-DLBCL versus 20 of 28 (71%) ABC-DLBCL patients had BCL2 expression higher than the median level.
Interestingly, within the ABC subtype (n=28), patients who experienced objective response to ibrutinib (CR + PR) had lower BCL2 gene expression ( Figure 2B ). In addition, ABC-DLBCL patients with lower BCL2 gene expression had a longer median progression-free survival (PFS) after ibrutinib therapy ( Figure 2C ).
Ibrutinib and ABT-199 synergistically inhibited cell growth of ABC-DLBCL, GCB-

DLBCL, and FL cells
Previous work (19) Figure 3B ). The isobologram shows how much less drug is required when it is used in combination compared with the single-agent doses needed to achieve a desired effect. Synergy between ABT-199 and ibrutinib was confirmed using isobologram analyses, synergy scores, and the CI obtained for each of the cell lines tested ( Figures 3C and 3D) . The combination of ibrutinib and ABT-199 was also confirmed to have synergistic growth suppressive effects in GCB-DLBCL (WSU-DLCL-2, RL, and SU-DHL-4) and FL (DoHH2 and WSU-FSCCL) cell lines, as shown by our cell viability results revealing a dose response shift toward a lower EC 50 (Figures 4A and   4B ) and by our CI analyses ( Figure 4C ).
Ibrutinib and ABT-199 synergistically suppressed cell growth in ibrutinibresistant ABC-DLBCL and FL cells
Given the synergy of ibrutinib and ABT-199 in parental ABC-DLBCL cells, we explored the effects of this combination in ibrutinib-resistant cells generated by genetic mutation (TMD8 [BTK-C481S] and OCI-LY10 [BTK-C481S]) or drug treatment (ibrutinib-resistant HBL1 and TMD8). Relative gene expression of total BTK in TMD8 (BTK-WT) and in TMD8 (BTK-C481S) was confirmed by qRT-PCR (Supplemental Figure 1A) . increased the sensitivity of both cell lines to ibrutinib treatment ( Figure 5A ). We observed that the effect of ABT-199 on ibrutinib sensitivity may be treatment timedependent as evidenced by the reduced effect of ABT-199 after a 3-day treatment in TMD8 (BTK-WT) cells compared with a 5-day treatment in the parental TMD8 cells ( Figure 3A) . We further generated OCI-LY10 (BTK-C481S) cells, which were confirmed to display approximately 300-fold resistance to ibrutinib compared with parental OCI- Figure 1B) . Consistently, ABT-199 sensitized OCI-LY10 (BTK-C481S) cells to ibrutinib ( Figures 5B and 5C) . A strong synergistic toxicity of ibrutinib and ABT-199 was confirmed by isobologram analysis of viability data ( Figure   5D ), as well as the CI obtained ( Figure 5E ). Consistent results were obtained in ibrutinib-resistant HBL1 and TMD8 cells ( Figure 5F ). In addition to ibrutinib-resistant ABC-DLBCL cells, the combination of ABT-199 and ibrutinib enhanced the sensitivity of ibrutinib-resistant DoHH2 cells to ibrutinib ( Figure 5G ), and synergy between these two compounds was demonstrated by the CI obtained ( Figure 5H ).
LY10 cells (Supplemental
Combining ibrutinib and ABT-199 increased apoptosis, inhibited colony formation, and suppressed tumor growth in ABC-DLBCL cells
In addition to the effects on cell growth, treatment of TMD8 cells with a combination of ibrutinib and ABT-199 resulted in increased cellular apoptosis ( Figure 6A ). We also evaluated the effect of this combination on the clonogenicity of HBL1 cells. While singleagent ibrutinib and ABT-199 significantly reduced the colony number, the combination of both compounds completely abrogated colony formation in the methylcellulose medium ( Figure 6B ). We next investigated the effect of this drug combination in a xenograft model of ABC-DLBCL. As a single agent, 12 mg/kg of ibrutinib or 40 mg/kg of ABT-199 only partially suppressed TMD8 tumor growth, whereas the combination of these agents produced full growth inhibition ( Figure 6C) . Notably, the apoptotic cell population significantly on October 28, 2017. © 2017 American Association for Cancer Research. mct.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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DISCUSSION
Although ibrutinib shows significant promise in ABC-DLBCL, it has limited efficacy as a single agent (5) . Fortunately, potential mechanisms by which to bypass this limitation are quickly being discovered (9, 20) . One approach to overcoming these obstacles is the use of combination therapy. BCL-2 inhibition in combination with other targeted therapies has demonstrated efficacy in several hematologic malignancies (21, 22) .
Consistent with previous high-throughput analyses (19) , we showed that ibrutinib and ABT-199 synergistically suppressed cell growth, reduced colony formation, increased apoptotic cell death, and inhibited tumor growth in an ABC-DLBCL mouse model. The combination effect of ibrutinib and ABT-199 is not limited to ABC-DLBCL. We also identified synergy between these two agents in both GCB-DLBCL and FL. Similar efforts have been utilized and promising results have been obtained for this combination strategy in other B-cell malignancies, including CLL (23), MCL (24, 25) , and Waldenström's macroglobulinemia (26) . Surprisingly, we also observed synergy between ibrutinib and ABT-199 in ibrutinib-resistant cell lines, both in cells selected in vitro for ibrutinib resistance and in those carrying a C481S-mutated form of BTK.
Deregulation of the antiapoptotic protein BCL-2 has been associated with resistance to targeted therapy and chemotherapy in cancers (27, 28) . We show in this study that on October 28, 2017. © 2017 American Association for Cancer Research. mct.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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Segregating ABC-DLBCL patients by BCL2 expression appears to identify a subpopulation of patients with worse PFS, consistent with our finding that patients with SD and PD during ibrutinib treatment have higher BCL2 expression than those with PR and CR. These data suggest the existence of an antiapoptotic mechanism that limits the impact of BTK inhibition.
Early studies indicated that ibrutinib interferes with the homing process of MCL cells and increases circulating tumor cells (29) . These circulating cells are more sensitive to ABT-199 than those attached to fibroblast cells (13) , providing the rationale for combining ibrutinib and ABT-199 in MCL. The finding discussed here that ibrutinib-resistant cells may have elevated sensitivity to ABT-199 due to compensatory upregulation of antiapoptotic proteins such as BCL-2 provides another molecular mechanism underlying the synergy between ibrutinib and ABT-199 in ABC-DLBCL cells. Whether there are other disease-dependent mechanisms accounting for this combination effect requires further investigation.
Several genes that were upregulated in ibrutinib-resistant cells according to our microarray analyses have been previously linked to ibrutinib resistance and development of lymphomas and leukemias. In a phase I/II clinical trial, ABC-DLBCL patients with tumors harboring mutations in both CD79B and MYD88 had a much higher ibrutinib response rate (4/5; 80%) than those with tumors containing WT CD79B and mutant MYD88 (0/7; 0%) (5 (30) . In addition, this study convincingly demonstrated that overexpression of WT CD79B induced tumor cell resistance to ibrutinib while depletion of CD79B sensitized tumor cells to ibrutinib. Consistently, our microarray analyses revealed that CD79B, among others, was significantly increased in ibrutinib-resistant TMD8 cells. Interestingly, TMD8 cells are known to be heterozygous for a CD79B mutation (4). Whether the increase in CD79B gene expression is of the WT or mutant form and whether these different forms play distinct functions in the cells requires further investigation. In addition to CD79B, we identified an increase in the BCR signaling-related gene PLCG2 in ibrutinib-resistant cells. This upregulation is consistent with previous findings identifying PLCG2 mutations in clinical samples from CLL patients with ibrutinib resistance and the role of PLCG2 in the formation of a BTK-bypass pathway (11, 31) .
Several additional genes that were upregulated in ibrutinib-resistant cells are known to be involved in the development of lymphomas or leukemias, including FOXP1 (32), IGF1R (33), and KDM1A (34) . Combining ibrutinib treatment with inhibitors targeting these proteins may prevent the formation of ibrutinib resistance.
Collectively, these data indicate that the combination of ibrutinib with ABT-199 may be highly effective in treating DLBCL and FL. Our data also implicate BCL-2 in resistance to single-agent ibrutinib therapy and suggest that disruption of this compensatory mechanism can shift the cell toward an apoptotic fate. Based on our findings in both in vitro and in vivo models, the combination of ibrutinib with ABT-199 appears promising and are currently being tested in clinical trials. 
